
Novartis has got its wallet out to pick up a Priority Review Voucher (PRV) from Ultragenyx, forking out $130 million …

Ultragenyx has revealed results from a Phase 3 trial into the treatment of GNE myopathy showed that its compound did …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

